Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Healthtrust
McKinsey
Federal Trade Commission
Mallinckrodt
Moodys
US Army
Fish and Richardson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,436,272

« Back to Dashboard

Summary for Patent: 5,436,272
Title: Treatment of obesity
Abstract:N,N-dimethyl-1-[ 1-(4-chlorophenyl)cyclobutyl] -3-methylbutylamine hydrochloride is used in the treatment of obesity in humans.
Inventor(s): Scheinbaum; Monte L. (Shreveport, LA)
Assignee: The Boots Company (USA), Inc. (Shreveport, IN)
Application Number:07/962,175
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,436,272
Patent Claims: 1. A method of treating obesity in humans which comprises administering by oral or parenteral means to a human in need thereof a therapeutically effective amount of N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride in conjunction with a pharmaceutically acceptable diluent or carrier.

2. A method as claimed in claim 1 wherein N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride is administered in the form of its monohydrate.

3. Method of claim 1, wherein the N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride is administered orally.

4. Method of claim 1, wherein the N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride is administered parenterally.

5. Method of claim 1, wherein the N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride is administered in an amount of from about 0.1 to about 50 mg per day.

6. Method of claim 5, wherein the amount is 1 to 30 mg per day.

7. Method of claim 1, wherein the N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride is administered in an amount from 2.5 to 20mg per day.

8. Method of claim 1, wherein the N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride is administered in an amount of about 10mg per day.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
Queensland Health
US Department of Justice
Chubb
Johnson and Johnson
Medtronic
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.